Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$4.58
+2.3%
$5.02
$3.42
$7.20
$255.21M1.751.57 million shs708,073 shs
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$30.37
-0.5%
$29.22
$23.23
$42.29
$975.20M0.64398,429 shs140,319 shs
89BIO stock logo
ETNB
89BIO
$10.14
+0.4%
$9.26
$4.16
$11.84
$1.48B1.281.52 million shs1.94 million shs
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
$6.97
+3.3%
$6.72
$5.04
$16.74
$1.08B-1.011.28 million shs652,460 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
+2.35%+7.39%-14.80%+14.09%-6.63%
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
-0.46%+1.57%+3.90%+7.92%-6.15%
89BIO stock logo
ETNB
89BIO
+0.40%+1.91%-0.29%+75.74%+35.56%
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
+3.26%-0.85%+7.23%+15.59%+31.02%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.1945 of 5 stars
0.01.00.00.01.60.80.6
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
4.1415 of 5 stars
3.41.00.03.02.10.82.5
89BIO stock logo
ETNB
89BIO
1.9373 of 5 stars
3.51.00.00.02.30.80.6
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
4.3752 of 5 stars
3.51.00.04.82.04.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
2.75
Moderate Buy$43.7544.06% Upside
89BIO stock logo
ETNB
89BIO
3.00
Buy$26.43160.64% Upside
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
2.92
Moderate Buy$20.50194.12% Upside

Current Analyst Ratings Breakdown

Latest ACB, WVE, ETNB, and COLL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
6/23/2025
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$18.00
6/11/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
6/11/2025
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$14.00
5/24/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
5/10/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
5/9/2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$36.00 ➝ $37.00
4/30/2025
89BIO stock logo
ETNB
89BIO
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/29/2025
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$10.00
4/24/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
4/9/2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$46.00 ➝ $46.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$246.72M1.04$0.62 per share7.43$7.78 per share0.59
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$631.45M1.55$12.35 per share2.46$7.10 per share4.28
89BIO stock logo
ETNB
89BIO
N/AN/AN/AN/A$3.34 per shareN/A
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
$108.30M10.01N/AN/A$1.37 per share5.09
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$1.63M$0.1141.5910.40N/A1.32%0.13%0.10%8/6/2025 (Estimated)
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$69.19M$1.2224.895.04N/A6.61%99.08%15.14%8/6/2025 (Estimated)
89BIO stock logo
ETNB
89BIO
-$367.08M-$3.38N/AN/AN/AN/A-81.44%-70.17%8/4/2025 (Estimated)
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
-$97.01M-$0.84N/AN/AN/AN/A-86.49%-37.20%8/6/2025 (Estimated)

Latest ACB, WVE, ETNB, and COLL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/18/2025Q4 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.11$0.07-$0.04-$0.24$88.85 million$63.34 million
5/8/2025Q1 2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$1.50$1.49-$0.01$0.07$174.96 million$177.76 million
5/8/2025Q1 2025
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
-$0.27-$0.29-$0.02-$0.29$11.65 million$9.18 million
5/1/2025Q1 2025
89BIO stock logo
ETNB
89BIO
-$0.50-$0.49+$0.01-$0.49N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/AN/AN/AN/AN/A
89BIO stock logo
ETNB
89BIO
N/AN/AN/AN/AN/A
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.13
4.31
2.16
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
3.30
1.08
1.01
89BIO stock logo
ETNB
89BIO
0.06
18.03
18.03
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
N/A
2.95
2.95

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/A
89BIO stock logo
ETNB
89BIO
N/A
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
89.73%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
2.51%
89BIO stock logo
ETNB
89BIO
2.60%
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
23.98%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,13056.21 million56.21 millionOptionable
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
21032.13 million31.33 millionOptionable
89BIO stock logo
ETNB
89BIO
40145.98 million142.19 millionOptionable
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
240155.56 million118.26 millionOptionable

Recent News About These Companies

Where WAVE Life Sciences Stands With Analysts
Brokers Offer Predictions for WVE FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$4.58 +0.11 (+2.35%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$4.57 -0.01 (-0.22%)
As of 07/3/2025 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Collegium Pharmaceutical stock logo

Collegium Pharmaceutical NASDAQ:COLL

$30.37 -0.14 (-0.46%)
Closing price 07/3/2025 01:48 PM Eastern
Extended Trading
$30.37 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

89BIO stock logo

89BIO NASDAQ:ETNB

$10.14 +0.04 (+0.40%)
Closing price 07/3/2025 02:41 PM Eastern
Extended Trading
$10.14 -0.01 (-0.05%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

WAVE Life Sciences stock logo

WAVE Life Sciences NASDAQ:WVE

$6.97 +0.22 (+3.26%)
Closing price 07/3/2025 03:00 PM Eastern
Extended Trading
$6.97 0.00 (0.00%)
As of 07/3/2025 04:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.